natgillin/translations-raw huggingface dataset:
stirring the mixture for a period of time, such as 10 minutes for example, at a temperature between the freezing point and the boiling point of the mixture, such as at room temperature for example, adding ethanol, followed by further stirring for a period of time, such as for 10 minutes for example; and, optionally, adding seed crystals, optionally followed by adding ethanol over a period of time such as within 5 hours for example; and, optionally, filtering off the resulting dihydrochloride of formula (II), optionally washing with a water-ethanol mixture and optionally drying, such as in vacuo for example, 
HR P20150138 T1 e) dodavanje zametaka kristala, proizvoljno nakon čega slijedi dodavanje etanola u vremenskom razdoblju od kao što je na primjer unutar 5 sati; te proizvoljno, 1) filtriranje dobivenog dihidroklorida sa formulom (ID), proizvoljno ispiranje sa smjesom voda-etanol i proizvoljno uz sušenje, kao što je na primjer in vacuo, čime se osigurava dihidrokloridna sol prema zahtjevu 1 ili 2.
the length of L4 is at least twice the length of L2; 
[2 je duljine 2 ostatka amino kiseline;
Of the disorders mentioned above, the treatment of anxiety, schizophrenia, migraine, depression, and epilepsy are of particular importance. 
Spoj ili sastav prema zahtjevu 8, naznačen time, da poremećaj središnjeg nervnog sustava je odabran iz skupine koju čine anksioznost, shizofrenija, migrena, depresija i epilepsija.
Preferably, the pharmaceutical composition of the present invention is prepared in suitable dosage forms comprising an effective amount of at least one compound of formula (I) as described above, a salt thereof with a pharmaceutically acceptable organic or inorganic acid or base, or a prodrug thereof, and at least one inert pharmaceutically acceptable excipient. 
Farmaceutski sastav, naznačen time, da on obuhvaća učinkovitu količinu najmanje jednog spoja formule (1) prema bilo kojem od zahtjeva 1 do 11, njegovu sol s farmaceutski prihvatljivom organskom ili anorganskom kiselinom ili lužinom, ili njegovu estersku prosupstancu, te najmanje jedno inertno farmaceutski prihvatljivo pomoćno sredstvo.
A nutraceutical compound as claimed in claim 1, comprising betulinic acid in an amount of less than or equal to 10%. 
Nutraceutički spoj prema patentnom zahtjevu 1, naznačen time, što sadrži betulinsku kiselinu u količini manjoj od ili jednakoj 10%.
A pharmaceutical composition comprising the antibody or antigen-binding fragment thereof that binds to CD38 according to claim 1, and a pharmaceutically acceptable carrier or excipient therefor. 
Farmaceutska kompozicija koja sadrži antitijelo prema patentnom zahtjevu 1 ili 2 1 farmaceutski prihvatljiv nosač ili ekscipijens.
A particular feature of example embodiments is that the martensitic transformation of the filler ingredient(s) can be provoked by a trigger mechanism (see further below). 
Posebna karakteristika ovog izuma je da je martenzitska transformacija materijala za punjenje može biti izazvana mehanizmom za poticanje (vidi dalje niže).
separating the pre-treated slurry of step a) into two parts, part A and part B; 
razdvajanja prethodno obrađene kaSe iz koraka a) u dva dijela, dio A 1 dio B;
curing the basecoat layer, wherein the aluminum powder comprises a particle size distribution characterized in that a 50th percentile of a particle size distribution has a diameter of between about 3.9 to 4.5 microns and a 90th percentile of a particle size distribution has a diameter of less than or equal to about 9.0 microns. 
Suspenzija prema bilo kojem od zahtjeva 1 do 2 pri čemu aluminijev prah ili prah aluminijeve legure ima distribuciju veličine čestica, naznačena time što 50. percentil distribucije veličine čestica ima promjer od između 3,9 do 4,5 um. 1 90. percentil distribucije veličine čestica ima promjer od manje od ili jednak 9,0 um.
To this purpose, according to another inventive aspect, it is provided a plurality of flow passages, disposed successively along the prevailing flow direction, whereby the distance between successive flow passages is previously dimensioned and the respective passageways develop in a substantially uniform manner radially, preferentially in asymmetric manner radially, relative to the central symmetry axis of the capsule. 
Kapsula u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačena time, da je opremljena većim brojem prolaza protoka (S1, S2, S3,...) postavljenih uzastopno duž glavnog smjera protoka, pri čemu se odgovarajući prolazi (8) razvijaju radijalno na uglavnom jednolik način, ponajprije radijalno na asimetričan način, u odnosu na središnju os simetrije kapsule (1).
50 20 A composition suitable for control of diseases caused by phytopathogens comprising (A) a compound of formula I wherein R1 is difluoromethyl or trifluoromethyl and X is chloro, fluoro or bromo; and (B) the compound cyprodinil. 
(A) spoja formule (I) naznačen time da R, je difluorometil ili trifluorometil i X je kloro, fluoro ili bromo; i (B) barem jednog spoja odabranog iz skupine koja se sastoji od (Bl) - strobilurin fungicida.
a prediction size determining unit configured to determine a size of a luma transform unit and a size of a chroma transform unit; 
jedinicu (330) za određivanje veličine predikcijskog bloka konfiguriranu da odredi veličinu luma transformacijske jedinice i veličinu kroma transformacijske jedinice primjenom informacija o veličini transformacije;
R is hydrogen, halogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C2-6 alkenyl, substituted or unsubstituted C2-6 alkynyl, substituted or unsubstituted C3-6 carbocyclyl, or -ORA2, wherein RA2 is hydrogen or substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C2-6 alkenyl, substituted or unsubstituted C2-6 alkynyl, or substituted or unsubstituted C3-6 carbocyclyl; 
R je vodik, halogen, supstituiran ili nesupstituiran C1-6 alkil, supstituiran ili nesupstituiran C2-6 alkenil, supstituiran ili nesupstituiran C2-6 alkinil, supstituiran ili nesupstituiran C3-6 karbociklil ili -ORA2, gdje RA2 je vodik ili supstituiran ili nesupstituiran C1-6 alkil, supstituiran ili nesupstituiran C2-6 alkenil, supstituiran ili nesupstituiran C2-6 alkinil ili supstituiran ili nesupstituiran C3-6 karbociklil;
Generally, the populations of particles defined above are believed to be particularly useful as filler ingredients in composite materials. 
Općenito, vjeruje se da su populacije gore definiranih čestica posebno korisne za sastojke za punjenje u kompozitnim materijalima.
The method according to claim 1, wherein the feed comprises a hydrocarbon selected from the group consisting of ethane, propane, butanes, naphthas, kerosenes, atmospheric gasoils, vacuum gasoils, heavy distillates, hydrogenated gasoils, gas condensates and mixtures thereof. 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time, da opskrbni materijal uključuje ugljikovodik odabran iz skupine koja sadrži etan, propan, butane, nafie, kerozine, atmosferska plinovita ulja, vakuumska plinovita ulja, teške distilatore, hidrizirana plinovita ulja, plinovite kondenzate i smjese navedenih.
The capsularhexis device (10) of claim 1, wherein the superelastic wire (14) is formed from a nickel titanium alloy. 
Naprava za kapsuloreksu (10) prema zahtjevu 1, naznačena time, da je visokoclastična žica (14) oblikovana od legure nikla i titana.
Thus, the normal functions associated with cross-linking of target antigen on cells are not ablated by the modified Fc variant. A method of altering binding of an IgG2 based Fc-containing molecule to FcY receptors as compared to a wildtype IgG2 based Fc, comprising altering the sequence of an Fc domain based on an IgG2 constant region at residues 233, 234, 235, 237, and 238 defined by the EU numbering system, to comprise a sequence selected from PAAAS (SEQ ID NO:5) and SAAAS (SEQ ID NO:6), and altering the IgG2 based Fc-containing molecule to further comprise mutations H268A or H268Q, V309L, A330S and P331S, wherein the binding of the IgG2 based Fc-containing molecule to FcY receptors is reduced as compared to a wildtype IgG2 based Fc. 
Molekula koja sadrži Fc prema zahtjevu 1, koja ima smanjen afinitet za Fcy receptore u usporedbi sa Fc divljeg tipa, obuhvaćajući Fc domenu antitijela baziranu na IgG2 konstantnoj regiji, gdje aminokiselinski ostaci 233, 234, 235, 237, 1 238 definirani EU sistemom numeracije, sadrže sekvencu izabranu iz PAAAP, PAAAS i SAAAS 1 dalje obuhvaćajući mutacije H268A ili H268Q, V309L, A330S i P3315 kao što je definirano EU sistemom numeracije. 15. Metoda promjene vezivanja IgG2 zasnovane molekule koja sadrži Fc na Fcy receptore u usporedbi sa IgG2 divljeg tipa zasnovanom na Fc, koji sadrži mijenjanje sekvence Fc domena baziranog na IgG2 konstantnoj regiji na ostacima 233, 234, 235, 237, 1 238, definirani EU sistemom numeracije, da sadrži sekvencu odabranu iz PAAAP, PAAAS i SAAAS, i obuhvaća mutacije H268A ili H268Q, V309L, A330S i P331S. s nos
The Emrys™ Optimiser microwave instrument (PersonalChemistry AB) is used in the standard configuration as delivered. 
Mikrovalni uređaj Emrys'" Optimiser (PersonalChemistry AB) upotrijebljen je u standardnoj konfiguraciji isporuke.
Adjustment of pumping rate can be calibrated for the substance and target product. 
Podešavanje kapaciteta pumpanja može se odrediti prema supstanci i ciljnom proizvodu.
The pharmaceutical composition of claim 15, wherein the ODT comprises drug particles and rapidly dispersing granules, wherein the drug particles comprise the corticosteroid, and the rapidly dispersing granules comprise the disintegrant and a sugar alcohol and/or saccharide. 
Tableta za oralno disperziranje sukladno patentnom zahtjevu 6, naznačeno time da tableta sadrži čestice lijeka i brzo raspršujuće granule, pri čemu čestice lijeka obuhvaćaju budezonid ili njegov solvat ili ester, dok brzo disperzirajuće granule sadrže najmanje jedno sredstvo za razgradnju i šećerni alkohol i/ili saharid.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidenebenzonorbornene-5-yl)amide and as component (B) chlorothalonil. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1 Hpirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-iljamid, te kao komponentu (B) spoj koji je izabran između slijedećeg: difenokonazola, propikonazola, kiprokonazola i epoksikonazola.
A precipitate formed which was subsequently collected by filtration. 
Formiran je talog koji je naredno sakupljen filtracijom.
an alcohol dehydration chamber (1) for converting the ethanol sample into ethene comprising means for purging the chamber; means for injecting a sample (2); heating means (5); a dehydration catalyst (7); and means for supplying carrier gas; 
- < komore za dehidraciju alkohola (1) za pretvaranje uzorka etanola u etilen koji sadrži sredstvo za čišćenje komore propuhivanjem; sredstvo za injektiranje uzorka (2); sredstva za grijanje (5); katalizator za dehidraciju (7), te sredstva za snabdijevanje plinovitim nosačem;
In a further aspect of the invention the amount of active substance is 120, 180 or 240 mg active substance. 
Sastav iz patentnog zahtjeva 1, pri čemu je količina u obliku doziranja 90, 120, 180, 240 ili 360 mg dimetilfumarata.
The protuberance and cavity can be made by altering the nucleic acid encoding the polypeptides, e.g. by site-specific mutagenesis, or by peptide synthesis. In a specific embodiment a knob modification comprises the amino acid substitution T366W in one of the two subunits of the Fc domain, and the hole modification comprises the amino acid substitutions T366S, L368A and Y407V in the other one of the two subunits of the Fc domain. 
Imunokonjugat u skladu s patentnim zahtjevom 3, naznačen time, da je navedena modifikacija modifikacija drške-u-šupljinu, koja obuhvaća modifikaciju drške u jednoj od dviju podjedinica Fc domene 1 modifikaciju šupljine u drugoj od dviju podjedinica Fc domene, pri čemu navedena modifikacija drške obuhvaća aminokiselinsku supstituciju T366W, a navedena modifikacija šupljine obuhvaća aminokiselinske supstitucije T366$, L368A i Y407V (EU numeracija).
Clause 10. The minimally invasive skin treatment device of clause 1, wherein the tool comprises an injection device and a nozzle, wherein the nozzle is configured to discharge a fluid in a direction parallel to the top of the handpiece and configured to increase a kinetic energy of the fluid when the fluid is injected by the injection device through the nozzle. 
Uređaj za minimalno invazivni tretman kože u skladu s patentnim zahtjevom 1, naznačen time, da alat obuhvaća napravu za ubrizgavanje i mlaznicu (1506), pri čemu je mlaznica konfigurirana za ispuštanje fluida u smjeru paralelnom s vrhom ručnog kompleta 1 oblikovana tako da povećava kinetičku energiju fluida kada se uštrcava tekućina kroz napravu za uštrcavanje kroz mlaznicu.
The method according to any one of items 1 to 17, wherein the one or more cells is cultured in at least 100 L of the supplemented basal cell culture media. The method according to any one of items 1 to 18, wherein the cell density is maintained at less than 2.5x106 cells per mL during the step of culturing the one or more cells. The method of item 19, wherein the cell density is maintained at less than 2.0x106 cells per mL during the step of culturing the one or more cells. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 8, naznačen time što se jednu ili više stanica uzgaja u najmanje 100 1 kompletiranog osnovnog medija za uzgoj stanica. Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 9, naznačen time što se gustoću stanica održava kod manje od 2,5 x 10" stanica na ml u koraku uzgoja jedne ili više stanica, manje od 2,0 x 10" stanica na ml u koraku uzgoja jedne ili više stanica, ili manje od 1,5 x 10" stanica na ml u koraku uzgoja jedne ili više stanica.
A compound or pharmaceutically acceptable salt thereof according to claims 1 to 9 for use in the treatment of pain associated with osteoarthritis or rheumatoid arthritis. 
Spoj, ili njegova farmaceutski prihvatljiva sol, u skladu s patentnim zahtjevima 1 do 9, naznačen time što je namijenjen upotrebi u liječenju boli povezane s osteoartritisom ili reumatoidnim artritisom.
n is 0; is hydrogen; and X is CH; 
Rs je vodik; i X je CH; ili njegova farmaceutski prihvatljiva sol.
The assembly of claim 1, wherein the frame has a plurality of openings and portions of the leaflet structure protrude through the openings while the prosthetic valve is in the radially collapsed configuration. 
Sklop prema patentnom zahtjevu 1, naznačen time da dijelovi strukture listića (14) štrče kroz otvore dok je protetski aortni ventil (10) u radijalno srušenom obliku.
and R5 together with the carbon to which they are attached form a cycloalkyl ring; is hydrogen, alkyl, alkoxyalkyl, alkylcarbonyl, alkylthiocarbonyl or unsubstituted or substituted benzyl, whereby the substituents may each be independent of one another and are selected from the group consisting of cyano, nitro, halogen, alkyl, haloalkyl, alkylthio, haloalkylthio, arylthio, alkoxy, haloalkoxy, alkylcarbonyl, haloalkylcarbonyl, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, alkylamino, di(alkyl)amino; 
Rx i Rs, zajedno s ugljikom na kojega su priključeni, tvore cikloalkilni prsten; Rgje vodik, alkil, alkoksialkil, alkilkarbonil, alkiltiokarbonil ili nesupstituirani ili supstituirani benzil, gdje supstituenti mogu biti svaki neovisan jedan od drugoga i odabrani su iz skupine koja se sastoji od sljedećih: cijano, nitro, halogen, alkil, haloalkil, alkiltio, haloalkiltio, ariltio, alkoksi, haloalkoksi, alkilkarbonil, haloalkilkarbonil, alkilsulfinil, haloalkilsulfinil, alkilsulfonil, haloalkilsulfonil, alkilamino, di(alkil)amino;
the marking members (70, 170) are mounted to the striking head (12). 
da su dijelovi označavanja (70, 170) monitirani na udarnu glavu (12).
A pharmaceutical composition comprising the compound N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1H-quinoline-3-carboxamide, or a pharmaceutically acceptable salt thereof, wherein said composition further comprises: 
Spoj N-(5-hidroksi-2,4-diterc-butil-fenil)-4-okso-1H-kinolin-3-karboksamid ili njegova farmaceutski prihvatljiva sol.
Analysis of the tertiary objective: 
Broj objave europskog patenta:
Item 2. The use of an AAV vector comprising a gene of interest for the manufacture of a medicament for delivering the gene to spinal cord by peripheral administration of said AAV vector to said subject, wherein said AAV vector is a double-stranded self-complementary AAV vector. 
AAV vektor koji sadrži gen od interesa za uporabu u metodi za dostavu navedenog gena od interesa kralježničnoj moždini intraperitonealnim (i.p.), intramuskularnim (i.m.) ili intravenskim (i.v.) injiciranjem, poželjno intravenskim injiciranjem, navedenog AAV vektora subjektu, pri čemu je navedeni AAV vektor:
The compound or a pharmaceutically acceptable salt thereof or composition for use according to claim 17 in combination with a second agent, wherein the disease is Chagas disease and the second agent is selected from benznidazole, nifurtimox and Amphotericin. 
Spoj ili njegova farmaceutski prihvatljiva sol ili pripravak za uporabu prema zahtjevu 17, naznačen time, da se nalazi u kombinaciji s drugim sredstvom, pri čemu je bolest Chagasova bolest 1 drugo sredstvo je odabrano od benznidazola, nifurtimoksa i amfotericina.
the nuclease agent, wherein the nuclease agent induces a nick or double-strand break at the recognition site; and 
agensa nukleaze, pri čemu taj agens nukleaze inducira prekidanje nickova ili dvostrukog lanca pri prepoznavanju; i
a monitoring and control unit; 
- > nadzornu i kontrolnu jedinicu (21);
a compound defined by the formula 1 wherein 
(1i) spoj definiran formulom 1
The covering layer 7 or 8 on the outside or inside of the building may be provided on the wall elements 2 before the windows and/or doors are positioned in the respective openings in the wall element 2. 
Pokrovni sloj 7 ili 8 s vanjske ili unutarnje strane građevine može se osigurati na zidnim elementima 2 prije nego se prozori i/ili vrata postave u odgovarajuće otvore u zidnim elementima 2.
The separated white solid is filtered, triturated, washed with water, dried over KOH and purified by washing with n-hexane, adding 200 ml of solvent under strong stirring. 
Izdvojena bijela krutina je filtrirana, razmuljena, prana vodom, sušena iznad KOH 1 prana n-heksanom uz dodatak 200 mL otapala uz intenzivno miješanje.
trifluoromethyl, O-alkyl1, carboxyl, cyano, nitro, formyl, hydroxy, NH-alkyl1, N(alkyl1)(alkyl1), and amino, the latter nitrogen substituents optionally in the form of a basic nitrogen functionality; 
- trifluorometil, O-alkil', karboksil, cijano, nitro, formil, hidroksi, NH-alkil!, N(alkil'\(alkil') i amino grupe, od kojih je potonji azidni supstituent fakultativno u obliku odgovarajuće osnovne azidne funkcije;
E is a methyl linker which is substituted by aminomethyl, wherein the amino group of the aminomethyl is unsubstituted, or mono- or disubstituted by LA, or E is a methyl linker which is substituted by (azetidin-1-yl)methyl, in Subformula 10 
E je metilna poveznica koja je supstituirana s aminometilom, pri čemu je amino skupina od aminometila nesupstituirana, ili mono- ili disupstituirana s LA, ili E je metilna poveznica koja je supstituirana s (azetidin-1-il)metil, ili u Podformuli 10
The reaction mixture was evaporated to dryness. 
Reakcijska smjesa se upari do suha.
Device according to one of the preceding claims, characterized in that the water outlet (3) is a tube with holes. 
Uređaj u skladu s jednim od prethodnih patentnih zahtjeva, naznačen time da odvod vode (3) je cijev sa rupama.
1, 2, 16, and 21 for the manufacture of a medicament for treating disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes insipidus, or sleep apnea. 
Uporaba spoja u skladu s bilo kojim zahtjevom 1 do 11, naznačena time, da se koristi za izradu lijeka za liječenje poremećaja središnjeg živčanog sustava; oštećenja središnjeg živčanog sustava; kardiovaskularnog poremećaja; gastrointestinalnog poremećaja; dijabetesa insipidusa ili apneje spavanja.
represents a group selected from C1-C3-alkyl-, halo-C1-C3-alkyl-, or a benzyl group, the phenyl group of which is optionally substituted with one or two substituents, identically or differently, selected from the group of halogen, C1-C3-alkyl-, C1-C3-alkoxy-, —NH2, alkylamino-, dialkylamino-; R10, R11 represent, independently from each other, a group selected from hydrogen, C1-C3-alkyl-, benzyl, or R10 and R11, together with the nitrogen atom they are attached to, form a cyclic amine; 
R* predstavlja skupinu koja je odabrana od skupine C,-C;-alkil-, halo-C,-C;-alkil-, ili benzil, čija je fenilna skupina proizvoljno supstituirana s jednim ili dva supstituenta, identično 1li različito, odabranim iz skupa koji čine halogen, C,-C2-alkil-, C,-C3-alkoksi-, -NH., alkilamino-, dialkilamino-; R'%, R' predstavljaju, međusobno neovisno, skupinu koja je odabrana od vodika, C,-C;-alkila-, benzila, ili R!"iR!', zajedno s atomom dušika na koji su oni vezani, tvore ciklički amin;
Process for preparing self-binding pigment particles comprising the following steps: providing an aqueous mineral pigment material suspension; providing at least one polymeric binder, wherein the binder comprises at least one carboxymethylcellulose having a degree of carboxylation in the range of 0.4 to 2.0 and having an intrinsic viscosity in the range of 3 to 300 ml/g; 
Postupak pripreme samoljepljivih pigmentnih čestica koji obuhvaća sljedeće korake: a) nabava vodene suspenzije mineralnog pigmentnog materijala; b) nabava barem jednog polimernog veziva, gdje vezivo sadrži barem jednu karboksimetilcelulozu sa stupnjem karboksilacije u rasponu od 0.4 do 2.0 1 s intrinzičnom viskoznosti u rasponu od 3 do 300 ml/g;
1 B A compound of Formula I: 
Spoj naznačen time, da ima formulu I:
In another embodiment, the protein of interest is FVIII. In another embodiment, the protein of interest is rFVIII. Another embodiment includes a method of manufacturing and recovering a protein of interest comprising: recombinantly producing a protein of interest using a host cell within a medium; filtering the medium using depth filtration; exposing the depth filter to an elution buffer to release protein of interest from the filter; recovering released protein of interest from the elution buffer; and recovering further protein of interest from the sample passed through the depth filter. 
Metoda za proizvodnju i obnavljanje proteina od interesa obuhvaća: rekombinantnu proizvodnju proteina od interesa koristeći stanicu domaćina unutar medija; filtriranje medija koristeći dubinski filtar s pozitivnim nabojem; izlaganje pozitivno nabijenog dubinskog filtra soli elucijskog pufera zbog oslobađanja proteina od interesa iz filtra, pri čemu sol elucijskog pufera ima provodljivost od najmanje 20 mS/em; obnavljanje oslobođenog proteina od interesa iz elucijskog pufera; obnavljanje daljnjeg proteina od interesa iz uzorka koji je prošao kroz dubinski filtar.
It is to be understood that the phraseology or terminology herein is for the purpose of description and not of limitation, such that the terminology or phraseology of the present specification is to be interpreted by the skilled artisan in light of the teachings and guidance presented herein, in combination with the knowledge of one of ordinary skill in the art. 
Podrazumijeva se da frazeologija ili terminologija koja se ovdje koristi je prilagođena u svrsi boljeg opisa, ali bez ograničavanja tako da terminologija ili frazeologija ove specifikacije treba biti razumljiva stručnjaku sukladno poučavanju i uputama ovdje predstavljenih te u kombinaciji sa znanjem uobičajenog stručnjaka u polju. Primjer 1: